UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549  
 
FORM 8-K  
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 6, 2017
 
American Renal Associates Holdings, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
001-37751
 
27-2170749
(State or other jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification Number)

500 Cummings Center, Suite 6550
Beverly, Massachusetts
 
01915
(Address of registrant’s principal executive office)
 
(Zip code)
(978) 922-3080
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 203.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
☒
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☒
 




 
 
 
Item 8.01.
Other Events.

On March 8, 2017, the Company filed its Annual Report on Form 10-K for the year ended December 31, 2016 (the “Form 10-K”), which included the report of the Company’s independent registered public accounting firm, Grant Thornton LLP, relating to the Company’s consolidated financial statements and financial statement schedule included in the Form 10-K. The Company is filing as Exhibit 23.1 hereto the consent of Grant Thornton LLP to the incorporation by reference of their report into the Company’s registration statement on Form S-8 (File No. 333-210870). This consent supersedes and replaces the consent filed as Exhibit 23.1 to the Form 10-K but does not change any previously reported financial results or other disclosure contained in the Form 10-K.

 
 
Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits.
 
Exhibit
Number
 
Description
23.1
 
Consent of Independent Registered Public Accounting Firm


 

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
AMERICAN RENAL ASSOCIATES HOLDINGS, INC.
 
 
 
 
Dated: June 6, 2017
 
 
 
By:
 
/s/ Jonathan L. Wilcox
 
 
 
 
Name:
 
Jonathan L. Wilcox
 
 
 
 
Title:
 
Chief Financial Officer

 
EXHIBIT INDEX
 
 
 
Exhibit
Number
 
Description
23.1
 
Consent of Independent Registered Public Accounting Firm



American Renal Associates (NYSE:ARA)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more American Renal Associates Charts.
American Renal Associates (NYSE:ARA)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more American Renal Associates Charts.